Eric Schmidt
2021
In 2021, Eric Schmidt earned a total compensation of $3.5M as Chief Financial Officer at Allogene Therapeutics, a 39% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $180,500 |
---|---|
Option Awards | $1,963,489 |
Salary | $475,000 |
Stock Awards | $839,973 |
Total | $3,458,962 |
Schmidt received $2M in option awards, accounting for 57% of the total pay in 2021.
Schmidt also received $180.5K in non-equity incentive plan, $475K in salary and $840K in stock awards.
Rankings
In 2021, Eric Schmidt's compensation ranked 3,874th out of 12,415 executives tracked by ExecPay. In other words, Schmidt earned more than 68.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,874 | 69th |
Manufacturing | 1,587 | 71st |
Chemicals And Allied Products | 650 | 73rd |
Drugs | 578 | 72nd |
Biological Products, Except Diagnostic Substances | 153 | 66th |
Schmidt's colleagues
We found four more compensation records of executives who worked with Eric Schmidt at Allogene Therapeutics in 2021.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019